TRCT
RANI icon

Tower Research Capital (TRC)’s Rani Therapeutics RANI Stock Holding History

Tower Research Capital (TRC)’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.6K Buy
29,743
+17,425
+141% +$15.4K ﹤0.01% 3446
2026
Q1 		$9.05K Buy
12,318
+4,633
+60% +$5.92K ﹤0.01% 3942
2025
Q4 		$10.4K Buy
7,685
+1,461
+23% +$2.2K ﹤0.01% 3785
2025
Q3 		$3.11K Sell
6,224
-3,061
-33% -$1.59K ﹤0.01% 4544
2025
Q2 		$4.77K Buy
+9,285
New +$7.58K ﹤0.01% 4270
2024
Q4 		– Sell
-1,721
Closed -$3.72K – 5943
2024
Q3 		$3.72K Sell
1,721
-12,716
-88% -$36.4K ﹤0.01% 4788
2024
Q2 		$54.9K Buy
14,437
+13,198
+1,065% +$68.4K ﹤0.01% 3030
2024
Q1 		$3.85K Sell
1,239
-1,069
-46% -$3.68K ﹤0.01% 4780
2023
Q4 		$7.66K Buy
+2,308
New +$5.34K ﹤0.01% 4593
2023
Q3 		– Sell
-7,048
Closed -$29K – 6180
2023
Q2 		$29K Buy
7,048
+3,211
+84% +$14.9K ﹤0.01% 3051
2023
Q1 		$20K Buy
3,837
+1,330
+53% +$8K ﹤0.01% 3440
2022
Q4 		$15K Buy
2,507
+1,129
+82% +$8.23K ﹤0.01% 3446
2022
Q3 		$13K Sell
1,378
-205
-13% -$2.17K ﹤0.01% 4285
2022
Q2 		$16K Buy
1,583
+1,045
+194% +$12K ﹤0.01% 4021
2022
Q1 		$7K Sell
538
-2,108
-80% -$35K ﹤0.01% 4753
2021
Q4 		$43K Buy
+2,646
New +$60.1K ﹤0.01% 2887

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Tower Research Capital (TRC)'s RANI Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Rani Therapeutics (RANI) stake by 141% in Q2 2026, buying an estimated $15.4K and bringing the position to 29,743 shares worth $22.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3446.

Tower Research Capital (TRC) first reported a position in RANI in Q4 2021 and has held it in 16 quarters since. The position peaked at $54.9K in Q2 2024. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Tower Research Capital (TRC) held 29,743 shares of Rani Therapeutics worth $22.6K as of Q2 2026.
  • Tower Research Capital (TRC) bought 17,425 Rani Therapeutics shares in Q2 2026, an estimated $15.4K.
  • Rani Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3446 holding.
  • Tower Research Capital (TRC) first reported a position in Rani Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • Tower Research Capital (TRC)'s Rani Therapeutics position peaked at $54.9K in Q2 2024.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.